CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic central nervous system malignancies. Their lead drug, Berubicin, is a next generation anthracycline that appears to cross the blood brain barrier and kill tumor cells in the brain. This represents a potentially new treatment for patients with glioblastoma multiforme (GMB), an aggressive and incurable form of brain cancer. CNS Pharmaceuticals is focused on developing novel drugs with the ultimate aim of advancing treatments for patients with primary or secondary brain cancers. Previously studied anthracyclines have limited efficacy in the brain due to their inability to cross the blood-brain barrier. At CNS Pharmaceuticals, pipeline products Berubicin and WP1244/WP1874 appear to penetrate the blood-brain barrier, differentiating them from other clinically available anthracyclines.